The effects on plasma 17-β-oestradiol (E 2), oestrone (E 1), LH, FSH and prolactin (PRL) levels of 1.5 mg conjugated oestrogen, administered daily per os for 20 consecutive days, was investigated in six postmenopausal women aged 60-68. Both E 2 and E 1 increased progressively and significantly (p<0.001) from 18 and 28 pg/ml to 32 and 108 pg/ml, respectively, at the end of treatment; five days after the last dose both E 2 and E 1 had fallen to pretreatment levels (p>0.05). LH and FSH decreased progressively and significantly (p<0.001) from 114 and 105 mIU/ml (before therapy) to 43 and 36 mIU/ml, respectively, after oestrogen administration. One week after interruption of treatment, both LH and FSH were significantly higher (p<0.001) than that obtained at the end of therapy. No significant variation (0.05>p>0.02) was observed for plasma PRL during and after oestrogen administration. Such results indicate that in postmenopausal women the specific enzymatic mechanism of oestrogen interconversion is maintained and that there is no increase of prolactin. In this way, the possible effects on the development of breast cancer by elevated levels of this hormone, usually observed during long-term oestrogen therapy, would be avoided.
Influence of coniugated oestrogens on circulating oestradiol, oestrone, LH, FSH and prolactin levels in postmenopausal women
BERNINI, GIAMPAOLO;
1981-01-01
Abstract
The effects on plasma 17-β-oestradiol (E 2), oestrone (E 1), LH, FSH and prolactin (PRL) levels of 1.5 mg conjugated oestrogen, administered daily per os for 20 consecutive days, was investigated in six postmenopausal women aged 60-68. Both E 2 and E 1 increased progressively and significantly (p<0.001) from 18 and 28 pg/ml to 32 and 108 pg/ml, respectively, at the end of treatment; five days after the last dose both E 2 and E 1 had fallen to pretreatment levels (p>0.05). LH and FSH decreased progressively and significantly (p<0.001) from 114 and 105 mIU/ml (before therapy) to 43 and 36 mIU/ml, respectively, after oestrogen administration. One week after interruption of treatment, both LH and FSH were significantly higher (p<0.001) than that obtained at the end of therapy. No significant variation (0.05>p>0.02) was observed for plasma PRL during and after oestrogen administration. Such results indicate that in postmenopausal women the specific enzymatic mechanism of oestrogen interconversion is maintained and that there is no increase of prolactin. In this way, the possible effects on the development of breast cancer by elevated levels of this hormone, usually observed during long-term oestrogen therapy, would be avoided.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
